ANEB — Anebulo Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Anebulo Pharmaceuticals Q2 net loss narrows
Brief: Anebulo Pharmaceuticals Announces Intention To Voluntarily Delist From Nasdaq And Deregister With SEC
Anebulo Pharmaceuticals posts Q1 net loss
Brief: Anebulo Pharmaceuticals Reports Fourth Quarter And Fiscal Year 2025 Financial Results
Anebulo rises as it weighs going-private deal after getting fresh options
Brief: Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives
U.S. RESEARCH ROUNDUP-GE Vernova, NVR, ServiceNow
Brief: Anebulo Pharmaceuticals Approves Plan To Terminate Registration Of Common Stock
Anebulo Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Anebulo Pharmaceuticals, Inc. Q3 Basic EPS USD -0.04
Anebulo Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Anebulo Pharmaceuticals Inc Files For Resale Of Up To 15.15 Million Shares By The Selling Stockholders
Brief: Anebulo Pharmaceuticals Inc Files Prospectus Related To Resale Of 15.2 Million Shares Of Common Stock By Selling Stockholders- SEC Filing
Anebulo Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Anebulo Pharmaceuticals Inc expected to post a loss of 8 cents a share - Earnings Preview
Anebulo Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Anebulo Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
Brief: Lifecore Biomedical Announces Cooperation Agreement With 22NW